NCT00663806CompletedPhase 4
EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Bayer
- Enrollment
- 7,614
- Primary Endpoint
- To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure.
Study Overview
Brief Summary
Safety and efficacy of Cipro XR in a naturalistic setting and the effectiveness of an educational brochure. - Women with urinary tract infections were treated with Cipro XR. They were also given a brochure with information about urinary tract infections and later tested on the information.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Ambulatory women outpatients 18 to 65 years of age with a documented clinical diagnosis of uUTI characterized by dysuria with either urgency or frequency. Women of childbearing age were enrolled only if they were highly unlikely to conceive during the study and were practicing a suitable method of birth control or were at least 1 year postmenopausal.
- •Positive leukocyte esterase (>/= 1+) and positive nitrite test using a urine dipstick method of analysis.
- •Willing to give written consent.
Exclusion Criteria
- •Pregnant or nursing
- •Complicated UTI
- •Allergy to Cipro XR
Outcomes
Primary Outcomes
To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure.
Time Frame: 3-10 days after start of therapy
Secondary Outcomes
- To examine the difference between physician and patient perceptions of the symptoms of uUTI.(At baseline visit pre-therapy)
- To collect data on the clinical efficacy and safety of Cipro XR, 500 mg, PO once daily, for 3 days, in the treatment of uUTI in a naturalistic setting.(1-3 days after end of therapy for efficacy and up to 30 days for safety)
Investigators
Similar Trials
Completed
Phase 3
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract InfectionsUrinary Tract InfectionNCT00668122Bayer212
Completed
Phase 4
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract InfectionsUrinary Tract InfectionNCT00676533Bayer276
Completed
Phase 4
Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract InfectionsUrinary Tract InfectionNCT00669994Bayer180
Completed
Phase 4
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common UropathogensUrinary Tract InfectionsNCT00481689Bayer500
Completed
Phase 1
Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/MesalamineHealthyNCT01402947Shire30